GeneDx Holdings/$WGS
WGS rises after reporting Q3 revenue of $116.7 M, beating the $104.3 M estimate, and raising full-year revenue guidance to $425–$428 M.
15 hours agoLightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GeneDx Holdings
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Ticker
$WGS
Sector
Primary listing
Employees
1,000
Headquarters
Website
GeneDx Holdings Metrics
BasicAdvanced
$4B
1,869.35
$0.07
-
-
Price and volume
Market cap
$4B
52-week high
$146.00
52-week low
$55.17
Average daily volume
526K
Financial strength
Current ratio
2.711
Quick ratio
2.465
Long term debt to equity
37.204
Total debt to equity
38.72
Interest coverage (TTM)
4.31%
Profitability
EBITDA (TTM)
34.717
Gross margin (TTM)
69.66%
Net profit margin (TTM)
0.52%
Operating margin (TTM)
2.91%
Effective tax rate (TTM)
16.91%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
1.62%
Return on equity (TTM)
0.84%
Valuation
Price to earnings (TTM)
1,869.348
Price to revenue (TTM)
9.682
Price to book
13.55
Price to tangible book (TTM)
37.04
Price to free cash flow (TTM)
251.768
Free cash flow yield (TTM)
0.40%
Free cash flow per share (TTM)
0.546
Growth
Revenue change (TTM)
50.50%
Earnings per share change (TTM)
-102.33%
3-year revenue growth (CAGR)
20.28%
3-year earnings per share growth (CAGR)
-86.62%
GeneDx Holdings News
AllArticlesVideos
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
Business Wire23 hours ago
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
Business Wire5 days ago
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
Business Wire7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GeneDx Holdings stock?
GeneDx Holdings (WGS) has a market cap of $4B as of October 29, 2025.
What is the P/E ratio for GeneDx Holdings stock?
The price to earnings (P/E) ratio for GeneDx Holdings (WGS) stock is 1869.35 as of October 29, 2025.
Does GeneDx Holdings stock pay dividends?
No, GeneDx Holdings (WGS) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next GeneDx Holdings dividend payment date?
GeneDx Holdings (WGS) stock does not pay dividends to its shareholders.
What is the beta indicator for GeneDx Holdings?
GeneDx Holdings (WGS) does not currently have a Beta indicator.